secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2025-06-17T23:59:59+00:00
Accession:  0001213900-25-055182
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology nearing commercial launch of LYMPHIR for CTCL in H2 2025
------------------------------------------------------------------------

- Commercial-scale manufacturing completed; inventory sufficient for 12-18 months post-launch with 60-month shelf life.
- 70 institutional oncology centers already registered via the LYMPHIR website.
- LYMPHIR included in NCCN guidelines; assigned permanent J-code for reimbursement.
- Parent Citius Pharma's recent capital raise supports final launch preparations.
- Strategic partnership discussions underway with financial advisor to expand market reach.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390025055182/0001213900-25-055182-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390025055182/ea0245933-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-055182

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer